ifmagic glp-1 Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review Current Insights, Advantages and Challenges
Description
TUESDAY, March 11, 2025 (HealthDay News) -- Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days
Medicaid Services proposed to expand Medicare Part D and Medicaid to cover weight loss drugs
Otolaryngologist patients with medullary thyroid cancer should not be taking GLP-1 medications at this time due to the risk.
According to William Hinojosa, DO, a general surgeon with Oklahoma Surgical Associates, the benefits of GLP-1 medications are significant, but its important for patients to understand potential side effects
To truly support patients on GLP-1 therapies, digital health and AI-powered tools are key
